Why smaller companies are the answer to benefitting from biotech industry changes

clock • 2 min read

Overuse of antibiotics around the globe has created a worrying increase in resistance to many commonly used drugs, writes Carl Harald Janson, lead manager on the International Biotechnology trust.

Superbugs are estimated to already account for 700,000 deaths a year and the problem will only get worse. In May, former Goldman Sachs economist Jim O'Neill published the Review on Microbial Resistance's final recommendations.  As well as suggesting a campaign to increase awareness of the problem, the report also suggests creating a $2bn global innovation fund and paying $1bn for every new antibiotic discovered. Biotech valuations at their lowest for years This recommendation to provide public funding to private companies highlights one of the key problems: these drugs are ofte...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

Trustpilot